The US Patent & Trademark Office (US PTO) has granted Gilead Sciences the patentability of US Patent No. 6,043,230 for Tenofovir which covers a method of use for Viread (tenofovir disoproxil fumarate).

Gilead Sciences has completed the first of four re-examination proceedings and has confirmed the patentability of US Patent No. 6,043,230, which covers a method of use for Viread (tenofovir disoproxil fumarate). The four US PTO review proceedings started in July 2007 in response to a challenge issued by the Public Patent Foundation (PUBPAT) in March 2007 for US Patents No. 5,922,695; 5,977,089; 5,935,946; and 6,043,230. In its request for the re-examinations, PUBPAT claimed that prior art existed that would have impacted the issuance of the original patents.
 
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide.